The US Food and Drug Administration on Monday approved a controversial new drug to treat Alzheimer’s disease for the first time in 20 years.
The FDA-approved drug, Aducanumab, also known as Aduhelm, attempts to fight the disease in its early stages by targeting beta-amyloid plaques in the brain to slow the disease’s progression.
-Advertisement-
And the US Food and Drug Administration announced in a statement that the drug had been granted “expedited approval” for use in the treatment of Alzheimer’s disease.
The decision comes after experts from the US Health Agency concluded last year that there was insufficient evidence to support the drug’s effectiveness.
